Role of yeasts in healthy and impaired gut microbiota: The gut mycome

Current Pharmaceutical Design

Volumn 20, Issue 28, 2014, Pages 4565-4569

  Ianiro, Gianluca ^a   Bruno, Giovanni ^a   Lopetuso, Loris ^a   Beghella, Francesca Bartoli ^a   Laterza, Lucrezia ^a   D'Aversa, Francesca ^a   Gigante, Giovanni ^a   Cammarota, Giovanni ^a   Gasbarrini, Antonio ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

Gut microbiota; Gut mycome; Saccharomyces boulardii; Yeasts

Indexed keywords

CANDIDA; CANDIDA ALBICANS; CHRONIC LIVER DISEASE; CROHN DISEASE; FILAMENTOUS FUNGUS; FUNGAL COMMUNITY; FUNGEMIA; FUNGUS; HUMAN; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SACCHAROMYCES BOULARDII; YEAST; ANIMAL; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; ISOLATION AND PURIFICATION; MICROBIOLOGY; MICROFLORA; SACCHAROMYCES;

PROBIOTIC AGENT;

ANIMALS; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; HUMANS; MICROBIOTA; PROBIOTICS; SACCHAROMYCES; YEASTS;

EID: 84904725561     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113196660723     Document Type: Review

References (69)

1. Scarpellini E, Cazzato A, Lauritano C, et al. Probiotics: which and when? Dig Dis 2008; 26(2): 175-82.
2. Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. Diversity, stability and resilience of the human gut microbiota. Nature 2012; 489(7415): 220-30.
3. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010; 464(7285): 59-65.
4. Kumamoto CA, Vinces MD. Alternative candida albicans lifestyle: growth on surfaces. Annu rev Microbial 2005; 59: 113-33.
5. Schulze J, Sonnenborn U. Yeasts in the gut: from commensals to infectious agents. Dtsch Arztebl Int 2009; 106(51-52): 837-42.
6. Scanlan PD, Marchesi JR. Micro-eukaryotic diversity of the human distal gut microbiota: qualitative assessment using culturedependent and-independent analysis of faeces. ISME J 2008; 2(12): 1183-93.
7. Young VB. The intestinal microbiota in health and disease. Curr opin gastroenterol 2012; 28(1): 63-9.
8. Maccaferri S, Biagi E, Brigidi P. Metagenomics: key to human gut microbiota. Dig dis 2011; 29(6): 525-30.
9. Nam YD, Chang HW, Kim KH, et al. Bacterial, archaeal, and eukaryal diversity in the intestines of Korean people. J Microbiol 2008; 46(5): 491-501.
10. Scanlan PD, Marchesi JR. Micro-eukaryotic diversity of the human distal gut microbiota: qualitative assessment using culturedependent and-independent analysis of faeces. ISME J 2008; 2(12): 1183-93.
11. Wu GD, Chen J, Hoffmann C, et al. Linking longterm dietary patterns with gut microbial enterotypes. Science 2011; 334: 105-8
12. Hoffmann C, Dollive S, Grunberg S, et al. Archaea and fungi of the human gut microbiome: correlations with diet and bacterial residents. PLoS One 2013; 8(6): e66019. doi: 10.1371/journal.pone.0066019. Print 2013. PMID: 23799070
13. Santamaría R, Rizzetto L, Bromley M, et al. Systems biology of infectious diseases: a focus on fungal infections. Immunobiology 2011; 216(11): 1212-27.
14. Falgier C, Kegley S, Podgorski H, et al. Candida species differ in their interactions with immature human gastrointestinal epithelial cells. Pediatr Res 2011; 69(5 Pt 1): 384-9
15. Gilchrist KB, Garcia MC, Sobonya R, Lipke PN, Klotz SA. New features of invasive candidiasis in humans: amyloid formation by fungi and deposition of serum amyloid P component by the host. J Infect Dis 2012; 206(9): 1473-8.
16. Burrus CJ. A biochemical rationale for the interaction between gastrointestinal yeast and autism. Med Hypotheses 2012 Dec; 79(6): 784-5.
17. Mason KL, Erb Downward JR, Mason KD, et al. Candida albicans and bacterial microbiota interactions in the cecum during recolonization following broad-spectrum antibiotic therapy. Infect Immun 2012; 80(10): 3371-80.
18. Cheng SC, et al. The dectin-1/inflammasome pathway is responsible for the induction of protective T-helper 17 responses that discriminate between yeasts and hyphae of Candida albicans. J Leukoc Biol 2011; 90: 357.
19. Gringhuis SI, et al. Dectin-1 is an extracellular pathogen sensor for the induction and processing of IL-1beta via a noncanonical caspase-8 inflammasome. Nat Immunol 2012
20. LeibundGut-Landmann S, et al. Syk-and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat Immunol 2007; 8: 630.
21. Conti HR, et al. Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J Exp Med 2009; 206: 299.
22. Ferwerda B, et al. Human dectin-1 deficiency and mucocutaneous fungal infections. N Engl J Med 2009; 361: 1760.
23. Glocker EO, et al. A homozygous CARD9 mutation in a family with susceptibility to fungal infections. N Engl J Med 2009; 361: 1727.
24. Taylor PR, et al. Dectin-1 is required for beta-glucan recognition and control of fungal infection. Nat Immunol 2007; 8: 31.
25. Franke A, et al. Genome-wide association study for ulcerative colitis identifies risk loci at 7q22 and 22q13 (IL17REL). Nat Genet 2010; 42: 292.
26. McGovern DP, et al. Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nat Genet 2010; 42: 332.
27. Seow CH, et al. Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype. Am J Gastroenterol 2009; 104: 1426.
28. Joossens S, et al. The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology 2002; 122: 1242.
29. Iliyan D. Iliev et al., Interactions between commensal fungi and the C-type lectin receptor Dectin-1 influence colitis, Science 2012; 336(6086): 1314-7.
30. Canonici A, Siret C, Pellegrino E, et al. Saccharomyces boulardii improves intestinal cell restitution through activation of the α2β1 integrin collagen receptor. PLoS One 2011; 6(3): e18427
31. Canonici A, Pellegrino E, Siret C, et al. Saccharomyces boulardii improves intestinal epithelial cell restitution by inhibiting αvβ5 integrin activation state. PLoS One 2012; 7(9): e45047
32. Standaert-Vitse A, Sendid B, Joossens M, et al. Candida albicans colonization and ASCA in familial Crohn's disease. Am J Gastroenterol 2009; 104(7): 1745-53.
33. Ott SJ, Kühbacher T, Musfeldt M, et al. Fungi and inflammatory bowel diseases: Alterations of composition and diversity. Scand J Gastroenterol 2008; 43: 831-41.
34. Chen Y, Chen Z, Guo R, et al. Correlation between gastrointestinal fungi and varying degrees of chronic hepatitis B virus infection. Diagn Microbiol Infect Dis 2011; 70: 492-8.
35. Bernhardt H. Knoke M. Mycological aspect of gastrointestinal microflora. Scand J Gastroenterol Suppl 1997; 222: 102-6
36. Agirbasli H, Ozcan SA, Gedikoglu G. Fecal fungal flora of pediatric healthy volunteers and immunosuppressed patients. Mycopathologia 2005; 159: 515-20
37. Payne S, Gibson G, Wynne A, Hudspith B, Brostoff J, Tuohy K. In vitrostudies on colonization resistance of the human gut microbiota to Candida albicans and the effects of tetracycline and Lactobacillus plantarum LPK. Curr Issues Intest Microbiol 2003; 4: 1-8.
38. MacKenzie DA Defernez M, Dunn WB, Brown M, Fuller et al. Relatedness of medically important strains of Saccharomyces cerevisiae as revealed by phylogenetics and metabolomics. Yeast 2008; 25: 501-12.
39. Malgoire JY, Bertout S, Renaud F, Bastide JM, Mallié M. Typing of Saccharomyces cerevisiae clinical strains by using microsatellite sequence polymorphism. J Clin Microbiol 2005; 43: 1133-7.
40. Pothoulakis C, Kelly CP, Joshi MA, et al. Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology 1993; 104: 1108-1579.
41. Brandao RL, Castro IM, Bambirra EA, et al. Intracellular signal triggered by cholera toxin in Saccharomyces boulardii and Saccharomyces cerevisiae. Appl Environ Microbiol 1998; 64: 564-8.
42. Castagliuolo I, Riegler MF, Valenick L, LaMont JT, Pothoulakis C. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun 1999; 67: 302-7.
43. Jahn HU, Ullrich R, Schneider T, et al. Immunological and trophical effects of Saccharomyces boulardii on the small intestine in healthy human volunteers. Digestion 1996; 57: 95-104.
44. Zbinden R, Bonczi E, Altwegg M. Inhibition of Saccharomyces boulardii on cell invasion of Salmonella typhimurium and Yersinia enterocolitica. Micro Ecol Health Dis.1999; 11: 158-62.
45. Czerucka D, Dahan S, Mograbi B, Rossi B, Rampal P. Saccharomyces boulardii preserves the barrier function and modulates the signal transduction pathway induced in enteropathogenic Escherichia coli-infected T84 cells. Infect Immun 2000; 68: 5998-6004.
46. Swidsinski A, Loening-Baucke V, Verstraelen H, Osowska S, Doerffel Y. Biostructure of fecal microbiota in healthy subjects and patients with chronic idiopathic diarrhea. Gastroenterology.2008; 135: 568-79100.
47. Barc MC, Charrin-Sarnel C, Rochet V, et al. Molecular analysis of the digestive microbiota in a gnotobiotic mouse model during antibiotic treatment: Influence of Saccharomyces boulardii. Anaerobe.2008; 14: 229-33.
48. Buts JP. Twenty-five years of research on Saccharomyces boulardii trophic effects: updates and perspectives. Dig Dis Sci 2009; 54: 15-8.
49. Chen X, Kokkotou EG, Mustafa N, et al. Saccharomyces boulardii inhibits ERK1/2 mitogen-activated protein kinase activation both in vitroand in vivoand protects against Clostridium difficile toxin Ainduced enteritis. J Biol Chem 2006; 281: 24449-54.
50. Lewis SJ, Potts LF, Barry RE. The lack of therapeutic effect of Saccharomyces boulardii in the prevention of antibiotic-related diarrhoea in elderly patients. J Infect 1998; 36: 171-4.
51. Adam J, Barret C, Barret-Bellet A, et al. Controlled double-blind clinical trials of Ultra-Levure: multi centre study by 25 physicians in 388 cases] Gazette Medicale de France 1977; 84: 2072-8.
52. Zocco MA, Garcovich M, Gasbarrini A. Saccharomyces boulardii and antibiotic-associated diarrhea: effectiveness of prophylactic use. Am J Gastroenterol 2012; 107(9): 1441.
53. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut 2012; 61(5): 646-64.
54. Cindoruk M, Erkan G, Karakan T, Dursun A, Unal S. Efficacy and safety of Saccharomyces boulardiiin the 14-day triple antiHelicobacter pylori therapy: a prospective randomized placebocontrolled double-blind study. Helicobacter 2007; 12: 309-16.
55. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994; 271: 1913-8.
56. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006; 101: 812-22.
57. Mansour-Ghanaei F, Dehbashi N, Yazdanparast K, Shafaghi A. Efficacy of saccharomyces boulardii with antibiotics in acute amoebiasis. World J Gastroenterol 2003; 9: 1832-3.
58. Hochter W, Chase D, Hagenhoff G. Saccharomyces boulardii in acute adult diarrhea: efficacy and tolerability of treatment. Munch Med Wschr 1990; 132: 188-92.
59. Kollaritsch H, Holst H, Grobara P, Wiedermann G. Prevention of traveler's diarrhea with Saccharomyces boulardii. Results of a placebo controlled double-blind study. Fortschr Med 1993; 111: 152-6.
60. Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 2003; 15: 697-8.
61. Plein K, Hotz J. Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn's disease with special respect to chronic diarrhea--a pilot study. Z Gastroenterol 1993; 31: 129-34.
62. Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000; 45: 1462-4.
63. Aupas JL, Champemont P, Delforge M. Treatment of irritable bowel syndrome. Double blind trial of Saccharomyces boulardii. Med Chir Dig 1983; 12: 77-9.
64. Temmerman R, Pot B, Huys G, Swings J. A quality analysis of commercial probiotic products. Meded Rijksuniv Gent FakLandbouwkd Toegep Biol Wet 2001; 66: 535, 537-535, 542.
65. Klein SM, Elmer GW, McFarland LV, Surawicz CM, Levy RH. Recovery and elimination of the biotherapeutic agent, Saccharomyces boulardii, in healthy human volunteers. Pharm Res 1993; 10: 1615-9.
66. Boyle RJ, Robins-Browne RM, Tang ML. Probiotic use in clinical practice: what are the risks? Am J Clin Nutr 2006; 83: 1256-64; quiz 1446-7.
67. Thygesen JB, Glerup H, Tarp B. Saccharomyces boulardii fungemia caused by treatment with a probioticum. BMJ Case Rep 2012 Mar 27; 2012. pii: bcr0620114412.
68. Elmer GW, Moyer KA, Vega R, et al. Evaluation of Saccharomyces boulardii for patients with HIV-related chronic diarrhoea and in healthy volunteers receiving antifungals. Microb Ther 1995; 25: 23-31.
69. Buts JP. Twenty-five years of research on Saccharomyces boulardii trophic effects: updates and perspectives. Dig Dis Sci 2009; 54: 15-8.